Cancer Specialty
Conference Coverage
- ASCO
- AACR 2024
- ASCO GI 2024
- ASH 2023
- SABCS 2023
- MOASC
- ASCO 2023

Advertisement

X (Twitter) LinkedIn Facebook

X (Twitter) LinkedIn Facebook

Cancer Specialty
Conference Coverage
- ASCO
- AACR 2024
- ASCO GI 2024
- ASH 2023
- SABCS 2023
- MOASC
- ASCO 2023

Home » PRODIGE 24 Showed FOLFIRINOX has Benefits | FOLFIRINOX was Compared to Single-Agent Gemcitabine

Pancreatic

PRODIGE 24 Showed FOLFIRINOX has Benefits | FOLFIRINOX was Compared to Single-Agent Gemcitabine

By EditorAugust 16, 2018No Comments1 Min Read

Twitter LinkedIn Facebook Email

Share

Twitter LinkedIn Facebook Email

Yung Lyou, MD, UC Irvine Health, talks PRODIGE 24 Showed FOLFIRINOX has Benefits | FOLFIRINOX was Compared to Single-Agent Gemcitabine at MOASC 2018

Follow on X (Twitter) Follow on LinkedIn Follow on Facebook Follow on Google News

Share. Twitter LinkedIn Facebook Email

Related Posts

Revolutionizing Pancreatic Cancer Detection: The Groundbreaking Role of Liquid Biopsies – Ajay Goel, PhD [AACR 2024]

Pancreatic 3 Mins Read

NAPOLI-3 Trial NALIRIFOX [2023] Slides – Chung, MD – MOASC

Pancreatic 3 Mins Read

SBRT Phase 2 Trial for Locally Advanced Pancreas Cancer

Pancreatic 3 Mins Read

Advertisement Sidebar

Recent Posts

BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Lead to Longevity Leaps?
Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer
Metastatic Breast Cancer: Trastuzumab (Herceptin) Factors for Long-Term Remission in HER2 negative
Breast Cancer New Nemeses: CDK4/6 Inhibitors Rave Against Recurrence, But Have They Crashed the EBC Party in NATALEE & monarchE’s Real-World Dance-Off?

Connect With Us on Social

Facebook
Twitter
LinkedIn

X (Twitter) LinkedIn Facebook

© 2025 Copyright Protected Medicus Networks, Inc..

Type above and press Enter to search. Press Esc to cancel.